12 results on '"José Valdez"'
Number of results to display per page
Search Results
2. PERFIL DE PACIENTES EM USO DE TERAPIA DUPLA COM DOLUTEGRAVIR E LAMIVUDINA, COORTE RETROSPECTIVA DE VIDA REAL
- Author
-
Iglessias, Ana Caroline Coutinho, primary, Madruga, José Valdez Ramalho, additional, Tancredi, Mariza Vono, additional, dos Santos Gouveia, João Paulo, additional, Ramos, Lucas Rocker, additional, Moraes, Camila de Albuquerque, additional, do Nascimento Kalmar, Erika Maria, additional, Sasaki, Marli, additional, Fonsi, Mylva, additional, Müller, Patrícia Rady, additional, Souza, Tatiany Viviany Gonçalves, additional, Carvalho, Daniel Gleison, additional, and Nogueira, Roberta Schiavon, additional
- Published
- 2023
- Full Text
- View/download PDF
3. Same-day initiation of oral pre-exposure prophylaxis among gay, bisexual, and other cisgender men who have sex with men and transgender women in Brazil, Mexico, and Peru (ImPrEP): a prospective, single-arm, open-label, multicentre implementation study
- Author
-
Valdiléa G Veloso, Carlos F Cáceres, Brenda Hoagland, Ronaldo I Moreira, Hamid Vega-Ramírez, Kelika A Konda, Iuri C Leite, Sergio Bautista-Arredondo, Marcus Vinícius de Lacerda, José Valdez Madruga, Alessandro Farias, Josué N Lima, Ronaldo Zonta, Lilian Lauria, Cesar Vidal Osco Tamayo, Hector Javier Salvatierra Flores, Yovanna Margot Cabrera Santa Cruz, Ricardo Martín Moreno Aguayo, Marcelo Cunha, Júlio Moreira, Alessandra Ramos Makkeda, Steven Díaz, Juan V Guanira, Heleen Vermandere, Marcos Benedetti, Heather L Ingold, M Cristina Pimenta, Thiago S Torres, Beatriz Grinsztejn, J. David Urbaez-Brito, Polyana d'Albuquerque, Claudio Palombo, Paulo Ricardo Alencastro, Raquel Keiko de Luca Ito, João L. Benedetti, Fabio V. Maria, Paula M. Luz, Lucilene Freitas, Kim Geraldo, Monica Derrico, Sandro Nazer, Tania Kristic, Renato Girade, Renato Lima, Antônio R. Carvalho, Carla Rocha, Pedro Leite, Marcio Lessa, Marilia Santini-Oliveira, Daniel R.B. Bezerra, Cleo de Oliveira Souza, Jacinto Corrêa, Marcelo Alves, Carolina Souza, Camilla Portugal, Mônica dos Santos Valões, Gabriel Lima Mota, Joyce Alves Gomes, Cynthia Ferreira Lima Falcão, Fernanda Falcão Riberson, Luciano Melo, Talita Andrade Oliveira, Agnaldo Moreira Oliveira Júnior, Bruna Fonseca, Leonor Henriette Lannoy, Ludymilla Anderson Santiago Carlos, João Paulo Cunha, Sonia Maria de Alencastro Coracini, Thiago Oliveira Rodrigues, Emília Regina Scharf Mettrau, Kelly Vieira Meira, Heder Tavares, Ana Paula Nunes Viveiros Valeiras, Taiane Miyake Alves de Carvalho Rocha, Alex Amorim, Patrícia Sabadini, Luiz Gustavo Córdoba, Caio Gusmão, Erika Faustino, Julia Soares da Silva Hansen, Agatha Mirian Cunha, Neuza Uchiyama Nishimura, Jaime Eduardo Flygare Razo Prereira Santos, Aline Barnabé Cano, Willyam Magnum Telles Dias, Magô Tonhon, Tania Regina Rezende, Alex Gomes, Eloá dos Santos Rodrigues, Maria das Dores Aires Carneiro, Alexandre Castilho, Mariana Carvalho, Dulce Diaz-Sosa, Centli Guillen-Diaz-Barriga, Lorena Hernández, Rebeca Robles, Maria Elena Medina-Mora, Marcela González, Ivonne Huerta Icelo, Araczy Martinez Davalos, José Gomez Castro, Luis Obed Ocampo Valdez, Fernanda Ramírez Barajas, Verónica Ruiz González, Galileo Vargas Guadarrama, Israel Macías, Jehovani Tena Sánchez, Juan Pablo Osuna Noriega, H. Rodrigo Moheno M, Jorge M. Bernal Ramírez, Víctor Dante Galicia Juarez, Gerardo Vizcaíno, Francisco Javier Arjona, Gino Calvo, Silver Vargas, Oliver Elorreaga, Ximena Gutierrez, Fernando Olivos, Damaris Caviedes, Daniella Adriazola, Eduardo Juárez, Gabriela Mariño, Jazmin Qquellon, Francesca Vasquez, Jean Pierre Jiron, Sonia Flores, and Karen Campos
- Subjects
Oral ,Prophylaxis ,Epidemiology ,Immunology ,Sex with men ,Cisgender ,Gay ,Infectious Diseases ,Virology ,Peru ,Transgender women ,Bisexual ,Mexico ,Brazil - Abstract
Although gay, bisexual, and other cisgender men who have sex with men (MSM) and transgender women have the highest HIV burden in Latin America, pre-exposure prophylaxis (PrEP) implementation is poor. We aimed to assess the feasibility of same-day oral PrEP delivery in Brazil, Mexico, and Peru.Implementation PrEP (ImPrEP) was a prospective, single-arm, open-label, multicentre PrEP implementation study conducted in Brazil (14 sites), Mexico (four sites), and Peru (ten sites). MSM and transgender women were eligible to participate if they were aged 18 years or older, HIV-negative, and reported one or more prespecified criteria. Enrolled participants received same-day initiation of daily oral PrEP (tenofovir disoproxil fumarate [300 mg] coformulated with emtricitabine [200 mg]). Follow-up visits were scheduled at week 4 and quarterly thereafter. We used logistic regression models to identify factors associated with early loss to follow-up (not returning after enrolment), PrEP adherence (medication possession ratio ≥0·6), and long-term PrEP engagement (attending three or more visits within 52 weeks). This study is registered at the Brazilian Registry of Clinical Trials, U1111-1217-6021.From Feb 6, 2018, to June 30, 2021, 9979 participants were screened and 9509 were enrolled (Brazil n=3928, Mexico n=3288, and Peru n=2293). 543 (5·7%) participants were transgender women, 8966 (94·3%) were cisgender men, and 2481 (26·1%) were aged 18-24 years. There were 12 185·25 person-years of follow-up. 795 (8·4%) of 9509 participants had early loss to follow-up, 6477 (68·1%) of 9509 were adherent to PrEP, and 5783 (70·3%) of 8225 had long-term PrEP engagement. Transgender women (adjusted odds ratio 1·60, 95% CI 1·20-2·14), participants aged 18-24 years (1·80, 1·49-2·18), and participants with primary education (2·18, 1·29-3·68) had increased odds of early loss to follow-up. Transgender women (0·56, 0·46-0·70), participants aged 18-24 years (0·52, 0·46-0·58), and those with primary education (0·60, 0·40-0·91) had lower odds of PrEP adherence. Transgender women (0·56, 0·45-0·71), participants aged 18-24 years (0·56, 0·49-0·64), and those with secondary education (0·74, 0·68-0·86) had lower odds of long-term PrEP engagement. HIV incidence was 0·85 per 100 person-years (95% CI 0·70-1·03) and was higher for transgender women, participants from Peru, those aged 18-24 years, Black and mixed-race participants, and participants who were non-adherent to PrEP.Same-day oral PrEP is feasible for MSM and transgender women in Latin America. Social and structural determinants of HIV vulnerability need to be addressed to fully achieve the benefits of PrEP.Unitaid, WHO, and Ministries of Health in Brazil, Mexico, and Peru.For the Portuguese and Spanish translations of the abstract see Supplementary Materials section.
- Published
- 2023
4. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial
- Author
-
Karin Hardt, An Vandebosch, Jerald Sadoff, Mathieu Le Gars, Carla Truyers, David Lowson, Ilse Van Dromme, Johan Vingerhoets, Tobias Kamphuis, Gert Scheper, Javier Ruiz-Guiñazú, Saul N Faust, Christoph D Spinner, Hanneke Schuitemaker, Johan Van Hoof, Macaya Douoguih, Frank Struyf, Brian T. Garibaldi, Timothy E. Albertson, Christian Sandrock, Janet S. Lee, Mark R. Looney, Victor F. Tapson, Charles Shey Wiysonge, Luis Humberto Anaya Velarde, Daniel Backenroth, Jisha Bhushanan, Börries Brandenburg, Vicky Cárdenas, Bohang Chen, Fei Chen, Polan Chetty, Pei-Ling Chu, Kimberly Cooper, Jerome Custers, Hilde Delanghe, Anna Duca, Tracy Henrick, Jarek Juraszek, Catherine Nalpas, Monika Peeters, Jose Pinheiro, Sanne Roels, Martin F. Ryser, Jose Salas, Samantha Santoro Matias, Ilse Scheys, Pallavi Shetty, Georgi Shukarev, Jeffrey Stoddard, Willem Talloen, NamPhuong Tran, Nathalie Vaissiere, Elisabeth van Son-Palmen, Jiajun Xu, Erin A. Goecker, Alexander L. Greninger, Keith R. Jerome, Pavitra Roychoudhury, Simbarashe G. Takuva, Jose Luis Accini Mendoza, Eric Achtyes, Habibul Ahsan, Azhar Alhatemi, Nancy Allen, Jose R. Arribas, Ghazaleh Bahrami, Lucia Bailon, Ali Bajwa, Jonathan Baker, Mira Baron, Susana Benet, Driss Berdaï, Patrick Berger, Todd Bertoch, Claire Bethune, Sybille Bevilacqua, Maria Silvia Biagioni Santos, Ian Binnian, Karen Bisnauthsing, Jean-Marc Boivin, Hilde Bollen, Sandrine Bonnet, Alberto M. Borobia, Elisabeth Botelho-Nevers, Phil Bright, Vianne Britten, Claire Brown, Amanda Buadi, Erik Buntinx, Lesley Burgess, Larry Bush, Maria Rosario Capeding, Quito Osuna Carr, Amparo Carrasco Mas, Hélène Catala, Katrina Cathie, T. Shawn Caudill, Fernando Cereto Castro, Kénora Chau, Steven Chavoustie, Marie Chowdhury, Nicolas Chronos, Paola Cicconi, Liliana Cifuentes, Sara Maria Cobo, Helen Collins, Hayley Colton, Carlos Rolando G. Cuaño, Valentino D'Onofrio, Paul Dargan, Thomas Darton, Peter Deane, Jose Luis Del Pozo, Inge Derdelinckx, Amisha Desai, Michael Dever, Beatriz Díaz-Pollán, Mark DiBuono, Matthew Doust, Christopher Duncan, Jose Maria Echave-Sustaeta, Frank Eder, Kimberly Ellis, Stanton Elzi, Stevan Emmett, Johannes Engelbrecht, Mim Evans, Theo Farah, Timothy Felton, João Pedro Ferreira, Catherine Floutier, Patrick Flume, Stacy Ford, Veronica Fragoso, Andrew Freedman, Emilia Frentiu, Christopher Galloway, Florence Galtier, Julia Garcia Diaz, Irene García García, Alcaide Garcia, Zoe Gardener, Pascale Gauteul, Steven Geller, Andrew Gibson, Claudia Gillet, Nicolas Girerd, Pierre-Olivier Girodet, Maria Tarcela Gler, Richard Glover, Herschel Don D. Go, Karishma Gokani, Damien Gonthier, Christopher Green, Richard Greenberg, Carl Griffin, Coert Grobbelaar, Adonis Guancia, Gloria Hakkarainen, James Harris, Michael Hassman, Deirdre Heimer, Elizabeth Hellstrom-Louw, Yoan Herades, Christopher Holroyd, Nazreen Hussen, Marie Grace Dawn Isidro, Yvonne Jackson, Manish Jain, Esaú Custódio João Filho, Daniel Johnson, Ben Jones, Natasha Joseph, Analyn Jumeras, Patricia Junquera, Johanna Kellett-Wright, Patrick Kennedy, Paul E. Kilgore, Kenneth Kim, Murray Kimmel, George Konis, Mark Kutner, Karine Lacombe, Odile Launay, Rajeka Lazarus, Samuel Lederman, Gigi Lefebvre, Katrina Lennon Collins, Isabel Leroux-Roels, Kenneth Wilson O. Lim, Muriel Lins, Edward Liu, Martin Llewelyn, Akbar Mahomed, Bernardo Porto Maia, Alícia Marín-Candon, Xavier Martínez-Gómez, Jean Benoit Martinot, Andrea Mazzella, Frank McCaughan, Louise McCormack, John McGettigan, Purvi Mehra, Rhonda Mejeur, Vicki Miller, Anthony Mills, Jose Molto Marhuenda, Prebashan Moodley, Marta Mora-Rillo, Beatriz Mothe, Daniel Mullan, Alasdair Munro, Paul Myers, Jeremy Nell, Tamara Newman Lobato Souza, Jane A. O'Halloran, Maria Dolores Ochoa Mazarro, Abigail Oliver, Jose Millan Onate Gutierrez, Jessica Ortega, Masaru Oshita, Susana Otero Romero, Jeffrey Scott Overcash, Daniel Owens, Alice Packham, Mihaela Pacurar, Leonardo Paiva de Sousa, Adrian Palfreeman, Christian José Pallares, Rahul Patel, Suchet Patel, Leslie Pelkey, Denise Peluso, Florentina Penciu, S. Jerry Pinto, Kevin Pounds, Joe Pouzar, Antoinette Pragalos, Rachel Presti, David Price, Ehsaan Qureshi, José Valdez Ramalho Madruga, Mayur Ramesh, Bruce Rankin, Béatrice Razat, Breno Riegel Santos, Robert Riesenberg, Ernie Riffer, Siobhan Roche, Katie Rose, Pietro Rosellini, Patrick Rossignol, Beth Safirstein, Hernan Salazar, Gregorio Sanchez Vallejo, Smrithi Santhosh, Enrique Seco-Meseguer, Michael Seep, Emma Sherry, Philip Short, Patrick Soentjens, Joel Solis, Alejandro Soriano Viladomiu, Caroline Sorli, Selwyn Spangenthal, Niamh Spence, Elaine Stephenson, Cynthia Strout, Ronald Surowitz, Kristy Michelle Taladua, David Tellalian, Claire Thalamas, Nang Thiriphoo, Judith Thomas, Nicholas Thomas, Guillermo Trout, Mikel Urroz, Bernard Veekmans, Laurent Veekmans, Ralph Elvi M. Villalobos, Sarah Warren, Brian Webster, Alexander White, Gail Williams, Hayes Williams, Barbara Wilson, Alan Winston, Martin Wiselka, and Marcus Zervos
- Subjects
Adult ,Vaccines ,COVID-19 Vaccines ,Immunogenicity, Vaccine ,Infectious Diseases ,Adolescent ,Ad26COVS1 ,Double-Blind Method ,SARS-CoV-2 ,Humans ,COVID-19 ,Antibodies, Viral - Abstract
Despite the availability of effective vaccines against COVID-19, booster vaccinations are needed to maintain vaccine-induced protection against variant strains and breakthrough infections. This study aimed to investigate the efficacy, safety, and immunogenicity of the Ad26.COV2.S vaccine (Janssen) as primary vaccination plus a booster dose.ENSEMBLE2 is a randomised, double-blind, placebo-controlled, phase 3 trial including crossover vaccination after emergency authorisation of COVID-19 vaccines. Adults aged at least 18 years without previous COVID-19 vaccination at public and private medical practices and hospitals in Belgium, Brazil, Colombia, France, Germany, the Philippines, South Africa, Spain, the UK, and the USA were randomly assigned 1:1 via a computer algorithm to receive intramuscularly administered Ad26.COV2.S as a primary dose plus a booster dose at 2 months or two placebo injections 2 months apart. The primary endpoint was vaccine efficacy against the first occurrence of molecularly confirmed moderate to severe-critical COVID-19 with onset at least 14 days after booster vaccination, which was assessed in participants who received two doses of vaccine or placebo, were negative for SARS-CoV-2 by PCR at baseline and on serology at baseline and day 71, had no major protocol deviations, and were at risk of COVID-19 (ie, had no PCR-positive result or discontinued the study before day 71). Safety was assessed in all participants; reactogenicity, in terms of solicited local and systemic adverse events, was assessed as a secondary endpoint in a safety subset (approximately 6000 randomly selected participants). The trial is registered with ClinicalTrials.gov, NCT04614948, and is ongoing.Enrolment began on Nov 16, 2020, and the primary analysis data cutoff was June 25, 2021. From 34 571 participants screened, the double-blind phase enrolled 31 300 participants, 14 492 of whom received two doses (7484 in the Ad26.COV2.S group and 7008 in the placebo group) and 11 639 of whom were eligible for inclusion in the assessment of the primary endpoint (6024 in the Ad26.COV2.S group and 5615 in the placebo group). The median (IQR) follow-up post-booster vaccination was 36·0 (15·0-62·0) days. Vaccine efficacy was 75·2% (adjusted 95% CI 54·6-87·3) against moderate to severe-critical COVID-19 (14 cases in the Ad26.COV2.S group and 52 cases in the placebo group). Most cases were due to the variants alpha (B.1.1.7) and mu (B.1.621); endpoints for the primary analysis accrued from Nov 16, 2020, to June 25, 2021, before the global dominance of delta (B.1.617.2) or omicron (B.1.1.529). The booster vaccine exhibited an acceptable safety profile. The overall frequencies of solicited local and systemic adverse events (evaluated in the safety subset, n=6067) were higher among vaccine recipients than placebo recipients after the primary and booster doses. The frequency of solicited adverse events in the Ad26.COV2.S group were similar following the primary and booster vaccinations (local adverse events, 1676 [55·6%] of 3015 vs 896 [57·5%] of 1559, respectively; systemic adverse events, 1764 [58·5%] of 3015 vs 821 [52·7%] of 1559, respectively). Solicited adverse events were transient and mostly grade 1-2 in severity.A homologous Ad26.COV2.S booster administered 2 months after primary single-dose vaccination in adults had an acceptable safety profile and was efficacious against moderate to severe-critical COVID-19. Studies assessing efficacy against newer variants and with longer follow-up are needed.Janssen ResearchDevelopment.
- Published
- 2022
5. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial
- Author
-
Hardt, Karin, primary, Vandebosch, An, additional, Sadoff, Jerald, additional, Le Gars, Mathieu, additional, Truyers, Carla, additional, Lowson, David, additional, Van Dromme, Ilse, additional, Vingerhoets, Johan, additional, Kamphuis, Tobias, additional, Scheper, Gert, additional, Ruiz-Guiñazú, Javier, additional, Faust, Saul N, additional, Spinner, Christoph D, additional, Schuitemaker, Hanneke, additional, Van Hoof, Johan, additional, Douoguih, Macaya, additional, Struyf, Frank, additional, Garibaldi, Brian T., additional, Albertson, Timothy E., additional, Sandrock, Christian, additional, Lee, Janet S., additional, Looney, Mark R., additional, Tapson, Victor F., additional, Wiysonge, Charles Shey, additional, Velarde, Luis Humberto Anaya, additional, Backenroth, Daniel, additional, Bhushanan, Jisha, additional, Brandenburg, Börries, additional, Cárdenas, Vicky, additional, Chen, Bohang, additional, Chen, Fei, additional, Chetty, Polan, additional, Chu, Pei-Ling, additional, Cooper, Kimberly, additional, Custers, Jerome, additional, Delanghe, Hilde, additional, Duca, Anna, additional, Henrick, Tracy, additional, Juraszek, Jarek, additional, Nalpas, Catherine, additional, Peeters, Monika, additional, Pinheiro, Jose, additional, Roels, Sanne, additional, Ryser, Martin F., additional, Salas, Jose, additional, Santoro Matias, Samantha, additional, Scheys, Ilse, additional, Shetty, Pallavi, additional, Shukarev, Georgi, additional, Stoddard, Jeffrey, additional, Talloen, Willem, additional, Tran, NamPhuong, additional, Vaissiere, Nathalie, additional, van Son-Palmen, Elisabeth, additional, Xu, Jiajun, additional, Goecker, Erin A., additional, Greninger, Alexander L., additional, Jerome, Keith R., additional, Roychoudhury, Pavitra, additional, Takuva, Simbarashe G., additional, Accini Mendoza, Jose Luis, additional, Achtyes, Eric, additional, Ahsan, Habibul, additional, Alhatemi, Azhar, additional, Allen, Nancy, additional, Arribas, Jose R., additional, Bahrami, Ghazaleh, additional, Bailon, Lucia, additional, Bajwa, Ali, additional, Baker, Jonathan, additional, Baron, Mira, additional, Benet, Susana, additional, Berdaï, Driss, additional, Berger, Patrick, additional, Bertoch, Todd, additional, Bethune, Claire, additional, Bevilacqua, Sybille, additional, Biagioni Santos, Maria Silvia, additional, Binnian, Ian, additional, Bisnauthsing, Karen, additional, Boivin, Jean-Marc, additional, Bollen, Hilde, additional, Bonnet, Sandrine, additional, Borobia, Alberto M., additional, Botelho-Nevers, Elisabeth, additional, Bright, Phil, additional, Britten, Vianne, additional, Brown, Claire, additional, Buadi, Amanda, additional, Buntinx, Erik, additional, Burgess, Lesley, additional, Bush, Larry, additional, Capeding, Maria Rosario, additional, Carr, Quito Osuna, additional, Carrasco Mas, Amparo, additional, Catala, Hélène, additional, Cathie, Katrina, additional, Caudill, T. Shawn, additional, Cereto Castro, Fernando, additional, Chau, Kénora, additional, Chavoustie, Steven, additional, Chowdhury, Marie, additional, Chronos, Nicolas, additional, Cicconi, Paola, additional, Cifuentes, Liliana, additional, Cobo, Sara Maria, additional, Collins, Helen, additional, Colton, Hayley, additional, Cuaño, Carlos Rolando G., additional, D'Onofrio, Valentino, additional, Dargan, Paul, additional, Darton, Thomas, additional, Deane, Peter, additional, Del Pozo, Jose Luis, additional, Derdelinckx, Inge, additional, Desai, Amisha, additional, Dever, Michael, additional, Díaz-Pollán, Beatriz, additional, DiBuono, Mark, additional, Doust, Matthew, additional, Duncan, Christopher, additional, Echave-Sustaeta, Jose Maria, additional, Eder, Frank, additional, Ellis, Kimberly, additional, Elzi, Stanton, additional, Emmett, Stevan, additional, Engelbrecht, Johannes, additional, Evans, Mim, additional, Farah, Theo, additional, Felton, Timothy, additional, Ferreira, João Pedro, additional, Floutier, Catherine, additional, Flume, Patrick, additional, Ford, Stacy, additional, Fragoso, Veronica, additional, Freedman, Andrew, additional, Frentiu, Emilia, additional, Galloway, Christopher, additional, Galtier, Florence, additional, Garcia Diaz, Julia, additional, García García, Irene, additional, Garcia, Alcaide, additional, Gardener, Zoe, additional, Gauteul, Pascale, additional, Geller, Steven, additional, Gibson, Andrew, additional, Gillet, Claudia, additional, Girerd, Nicolas, additional, Girodet, Pierre-Olivier, additional, Gler, Maria Tarcela, additional, Glover, Richard, additional, Go, Herschel Don D., additional, Gokani, Karishma, additional, Gonthier, Damien, additional, Green, Christopher, additional, Greenberg, Richard, additional, Griffin, Carl, additional, Grobbelaar, Coert, additional, Guancia, Adonis, additional, Hakkarainen, Gloria, additional, Harris, James, additional, Hassman, Michael, additional, Heimer, Deirdre, additional, Hellstrom-Louw, Elizabeth, additional, Herades, Yoan, additional, Holroyd, Christopher, additional, Hussen, Nazreen, additional, Isidro, Marie Grace Dawn, additional, Jackson, Yvonne, additional, Jain, Manish, additional, João Filho, Esaú Custódio, additional, Johnson, Daniel, additional, Jones, Ben, additional, Joseph, Natasha, additional, Jumeras, Analyn, additional, Junquera, Patricia, additional, Kellett-Wright, Johanna, additional, Kennedy, Patrick, additional, Kilgore, Paul E., additional, Kim, Kenneth, additional, Kimmel, Murray, additional, Konis, George, additional, Kutner, Mark, additional, Lacombe, Karine, additional, Launay, Odile, additional, Lazarus, Rajeka, additional, Lederman, Samuel, additional, Lefebvre, Gigi, additional, Lennon Collins, Katrina, additional, Leroux-Roels, Isabel, additional, Lim, Kenneth Wilson O., additional, Lins, Muriel, additional, Liu, Edward, additional, Llewelyn, Martin, additional, Mahomed, Akbar, additional, Maia, Bernardo Porto, additional, Marín-Candon, Alícia, additional, Martínez-Gómez, Xavier, additional, Martinot, Jean Benoit, additional, Mazzella, Andrea, additional, McCaughan, Frank, additional, McCormack, Louise, additional, McGettigan, John, additional, Mehra, Purvi, additional, Mejeur, Rhonda, additional, Miller, Vicki, additional, Mills, Anthony, additional, Molto Marhuenda, Jose, additional, Moodley, Prebashan, additional, Mora-Rillo, Marta, additional, Mothe, Beatriz, additional, Mullan, Daniel, additional, Munro, Alasdair, additional, Myers, Paul, additional, Nell, Jeremy, additional, Newman Lobato Souza, Tamara, additional, O'Halloran, Jane A., additional, Ochoa Mazarro, Maria Dolores, additional, Oliver, Abigail, additional, Onate Gutierrez, Jose Millan, additional, Ortega, Jessica, additional, Oshita, Masaru, additional, Otero Romero, Susana, additional, Overcash, Jeffrey Scott, additional, Owens, Daniel, additional, Packham, Alice, additional, Pacurar, Mihaela, additional, Paiva de Sousa, Leonardo, additional, Palfreeman, Adrian, additional, Pallares, Christian José, additional, Patel, Rahul, additional, Patel, Suchet, additional, Pelkey, Leslie, additional, Peluso, Denise, additional, Penciu, Florentina, additional, Pinto, S. Jerry, additional, Pounds, Kevin, additional, Pouzar, Joe, additional, Pragalos, Antoinette, additional, Presti, Rachel, additional, Price, David, additional, Qureshi, Ehsaan, additional, Ramalho Madruga, José Valdez, additional, Ramesh, Mayur, additional, Rankin, Bruce, additional, Razat, Béatrice, additional, Riegel Santos, Breno, additional, Riesenberg, Robert, additional, Riffer, Ernie, additional, Roche, Siobhan, additional, Rose, Katie, additional, Rosellini, Pietro, additional, Rossignol, Patrick, additional, Safirstein, Beth, additional, Salazar, Hernan, additional, Sanchez Vallejo, Gregorio, additional, Santhosh, Smrithi, additional, Seco-Meseguer, Enrique, additional, Seep, Michael, additional, Sherry, Emma, additional, Short, Philip, additional, Soentjens, Patrick, additional, Solis, Joel, additional, Soriano Viladomiu, Alejandro, additional, Sorli, Caroline, additional, Spangenthal, Selwyn, additional, Spence, Niamh, additional, Stephenson, Elaine, additional, Strout, Cynthia, additional, Surowitz, Ronald, additional, Taladua, Kristy Michelle, additional, Tellalian, David, additional, Thalamas, Claire, additional, Thiriphoo, Nang, additional, Thomas, Judith, additional, Thomas, Nicholas, additional, Trout, Guillermo, additional, Urroz, Mikel, additional, Veekmans, Bernard, additional, Veekmans, Laurent, additional, Villalobos, Ralph Elvi M., additional, Warren, Sarah, additional, Webster, Brian, additional, White, Alexander, additional, Williams, Gail, additional, Williams, Hayes, additional, Wilson, Barbara, additional, Winston, Alan, additional, Wiselka, Martin, additional, and Zervos, Marcus, additional
- Published
- 2022
- Full Text
- View/download PDF
6. Experimental behaviour of 3D end-plate beam-to-column bolted steel joints
- Author
-
Ricardo Costa, Eduardo Bayo, Sara Oliveira, José Valdez, and Luís Simões da Silva
- Subjects
Materials science ,business.industry ,0211 other engineering and technologies ,Stiffness ,020101 civil engineering ,02 engineering and technology ,Structural engineering ,0201 civil engineering ,Stress (mechanics) ,Column (typography) ,Cruciform ,021105 building & construction ,medicine ,Minor axis ,Boundary value problem ,medicine.symptom ,business ,Joint (geology) ,Beam (structure) ,Civil and Structural Engineering - Abstract
This work presents the experimental assessment of the joint behaviour of five steel beam-to-column end-plate joint configurations to assess (i) the effect of minor axis end plate joints in the behaviour of major axis end plate joints, and (ii) the interaction of two minor axis end plate joints. The experimental tests were performed with true size cruciform sub-frames specimens with boundary conditions intended to simulate unbraced frames. The sub-fames, with one to three beams, were loaded introducing multiple 3D stress states in the column unstiffened web, causing an interaction between the mechanical behaviour of two or three major and minor axis joints. The interactions were assessed in terms of the moment-rotation relations of joints, connections and column web. It was found that, for the slenderness of the column web tested, (i) the minor-axis joints have only a relevant influence on the stiffnesses of the major-axis joints and (ii) that, when two minor axis joints are present, their mutual interation increases both their stiffness and strength.
- Published
- 2019
7. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial
- Author
-
Beatriz, Grinsztejn, Nathalie, De Castro, Vincent, Arnold, Valdiléa G, Veloso, Mariza, Morgado, José Henrique, Pilotto, Carlos, Brites, José Valdez, Madruga, Nêmora Tregnago, Barcellos, Breno Riegel, Santos, Carla, Vorsatz, Catherine, Fagard, Marilia, Santini-Oliveira, Olivier, Patey, Constance, Delaugerre, Geneviève, Chêne, Jean-Michel, Molina, and B R, Santos
- Subjects
Adult ,Cyclopropanes ,Male ,medicine.medical_specialty ,Tuberculosis ,Efavirenz ,Anti-HIV Agents ,Antitubercular Agents ,Organophosphonates ,HIV Infections ,Raltegravir Potassium ,law.invention ,chemistry.chemical_compound ,Randomized controlled trial ,Acquired immunodeficiency syndrome (AIDS) ,law ,Internal medicine ,medicine ,Humans ,Tenofovir ,AIDS-Related Opportunistic Infections ,Coinfection ,business.industry ,Adenine ,Lamivudine ,Middle Aged ,Viral Load ,medicine.disease ,Raltegravir ,Pyrrolidinones ,Benzoxazines ,Surgery ,Treatment Outcome ,Infectious Diseases ,chemistry ,Alkynes ,HIV-1 ,RNA, Viral ,Drug Therapy, Combination ,Female ,France ,business ,Viral load ,Brazil ,medicine.drug - Abstract
Concurrent treatment of HIV and tuberculosis is complicated by drug interactions. We explored the safety and efficacy of raltegravir as an alternative to efavirenz for patients co-infected with HIV and tuberculosis.We did a multicentre, phase 2, non-comparative, open-label, randomised trial at eight sites in Brazil and France. Using a computer-generated randomisation sequence, we randomly allocated antiretroviral-naive adult patients with HIV-1 and tuberculosis (aged ≥18 years with a plasma HIV RNA concentration of1000 copies per mL) to receive raltegravir 400 mg twice a day, raltegravir 800 mg twice daily, or efavirenz 600 mg once daily plus tenofovir and lamivudine (1:1:1; stratified by country). Patients began study treatment after the start of tuberculosis treatment. The primary endpoint was virological suppression at 24 weeks (HIV RNA50 copies per mL) in all patients who received at least one dose of study drug (modified intention-to-treat analysis). We recorded death, study drug discontinuation, and loss to follow-up as failures to achieve the primary endpoint. We assessed safety in all patients who received study drugs. This study is registered in ClinicalTrials.gov, number NCT00822315.Between July 3, 2009, and June 6, 2011, we enrolled and randomly assigned treatment to 155 individuals; 153 (51 in each group) received at least one dose of the study drug and were included in the primary analysis. 133 patients (87%) completed follow-up at week 48. At week 24, virological suppression was achieved in 39 patients (76%, 95% CI 65-88) in the raltegravir 400 mg group, 40 patients (78%, 67-90) in the raltegravir 800 mg group, and 32 patients (63%, 49-76) in the efavirenz group. The adverse-event profile was much the same across the three groups. Three (6%) patients allocated to efavirenz and three (6%) patients allocated to raltegravir 800 mg twice daily discontinued the study drugs due to adverse events. Seven patients died during the study (one in the raltegravir 400 mg group, four in the raltegravir 800 mg group, and two in the efavirenz group): none of the deaths was deemed related to study treatment.Raltegravir 400 mg twice daily might be an alternative to efavirenz for the treatment of patients co-infected with HIV and tuberculosis.French National Agency for Research on AIDS and Viral Hepatitis (ANRS), Brazilian National STD/AIDS Program-Ministry of Health.
- Published
- 2014
8. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial
- Author
-
Grinsztejn, Beatriz, primary, De Castro, Nathalie, additional, Arnold, Vincent, additional, Veloso, Valdiléa G, additional, Morgado, Mariza, additional, Pilotto, José Henrique, additional, Brites, Carlos, additional, Madruga, José Valdez, additional, Barcellos, Nêmora Tregnago, additional, Santos, Breno Riegel, additional, Vorsatz, Carla, additional, Fagard, Catherine, additional, Santini-Oliveira, Marilia, additional, Patey, Olivier, additional, Delaugerre, Constance, additional, Chêne, Geneviève, additional, and Molina, Jean-Michel, additional
- Published
- 2014
- Full Text
- View/download PDF
9. Su1055 Impact of Baseline Variables on Response to Faldaprevir Plus Pegylated Interferon α-2A and Ribavirin in Patients With HIV/HCV Genotype-1 Coinfection in a Phase III Trial
- Author
-
Montserrat Manero, Wulf O. Böcher, Vicente Soriano, Cristina Tural, Mark T. Nelson, Patrick Ingiliz, Richard Vinisko, Sanjay Bhagani, Anne-Marie Quinson, Andri Rauch, Marina Núñez, José Valdez Madruga, Marc-Antoine Valantin, Jürgen K. Rockstroh, Jerry O. Stern, Juvencio Furtado, Douglas T. Dieterich, and Manuel Battegay
- Subjects
medicine.medical_specialty ,Hepatology ,business.industry ,Ribavirin ,Gastroenterology ,Pegylated interferon α ,medicine.disease ,chemistry.chemical_compound ,chemistry ,Internal medicine ,Faldaprevir ,Genotype ,medicine ,Coinfection ,In patient ,business - Published
- 2014
10. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial
- Author
-
Madruga, José Valdez, primary, Cahn, Pedro, additional, Grinsztejn, Beatriz, additional, Haubrich, Richard, additional, Lalezari, Jacob, additional, Mills, Anthony, additional, Pialoux, Gilles, additional, Wilkin, Timothy, additional, Peeters, Monika, additional, Vingerhoets, Johan, additional, de Smedt, Goedele, additional, Leopold, Lorant, additional, Trefiglio, Roberta, additional, and Woodfall, Brian, additional
- Published
- 2007
- Full Text
- View/download PDF
11. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial
- Author
-
Madruga, José Valdez, primary, Berger, Daniel, additional, McMurchie, Marilyn, additional, Suter, Fredy, additional, Banhegyi, Denes, additional, Ruxrungtham, Kiat, additional, Norris, Dorece, additional, Lefebvre, Eric, additional, de Béthune, Marie-Pierre, additional, Tomaka, Frank, additional, De Pauw, Martine, additional, Vangeneugden, Tony, additional, and Spinosa-Guzman, Sabrina, additional
- Published
- 2007
- Full Text
- View/download PDF
12. The structure–activity effect at Hairless protein of four point mutations on the Hairless gene
- Author
-
Alejandro Bravo-Patiño, Víctor Manuel Baizabal-Aguirre, Juan José Valdez-Alarcón, Marcos Cajero-Juárez, Anja C. Nagel, Annette Preiss, and null Maier
- Subjects
Hairless gene ,Point mutation ,Cell Biology ,Biology ,Molecular Biology ,Molecular biology ,Developmental Biology ,Hairless - Published
- 2007
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.